Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00218257 · ClinicalTrials.gov registry record · NA

Progesterone for the Treatment of Cocaine Dependence - 1

A NA study of Cocaine-Related Disorders and Cocaine Abuse, sponsored by University of Minnesota.

Completed
Registry status
NA
Development phase
96
Enrollment target
1
Study location

NCT00218257 is a NA study of Cocaine-Related Disorders and Cocaine Abuse that has completed, run by University of Minnesota. The registered enrollment target is 96 participants, above the 59-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (63% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00218257, a NA study of Cocaine-Related Disorders and Cocaine Abuse, has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
NA
Development phase
96 participants
Enrollment target
1
Study location

Study Summary

Past research has demonstrated that cocaine dependent women experience less severe responses to cocaine during the luteal phase of the menstrual cycle, when estrogen and progesterone concentrations are high. The purpose of this study is to determine whether administered progesterone reduces subjective and physiological responses to cocaine in cocaine dependent individuals.

Interventions

  • OTHER Placebo
  • DRUG Progesterone

Study Locations (1)

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2002-07
Est. Completion 2008-06-30
Phase NA

Sponsor

University of Minnesota

966 total trials

What the Registry Record Tells You About NCT00218257

The ClinicalTrials.gov registry entry for NCT00218257 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 59-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (63% higher). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cocaine-Related Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00218257 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT00218257 about?

NCT00218257 is a clinical study titled "Progesterone for the Treatment of Cocaine Dependence - 1". Past research has demonstrated that cocaine dependent women experience less severe responses to cocaine during the luteal phase of the menstrual cycle, when estrogen and progesterone concentrations are high. The purpose of this study is to determine whether administered progesterone reduces subjecti...

What is the current status of trial NCT00218257?

This trial is currently completed. It is a NA study. The enrollment target is 96 participants. The study started on 2002-07. Estimated completion is 2008-06-30.

What conditions does trial NCT00218257 study?

This clinical trial studies the following conditions: Cocaine-Related Disorders, Cocaine Abuse.

What interventions are being tested in trial NCT00218257?

The interventions under investigation include: Placebo (OTHER), Progesterone (DRUG).

Who is sponsoring clinical trial NCT00218257?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00218257 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cocaine-Related Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.